Rheumatoid Arthritis Management: Emerging Drug Therapies and Innovations

Rheumatoid Arthritis (RA) is a chronic systemic autoimmune disease characterized by persistent joint inflammation. Genetically predisposed conditions like Human Leukocyte Antigen DR1 (HLA-DR1) and Human Leukocyte Antigen DR4 (HLA-DR4), coupled with environmental insults like infection, smoking, diet, and stress, are etiological factors in immune dysregulation. It results in the overproduction of pro-inflammatory cytokines and autoantibodies, ultimately causing synovial inflammation and joint destruction. The objective of this review is to highlight the latest developments in RA management through new drug formulations, targeted biologics, and novel Drug Delivery Systems (DDS).

A systematic literature search of scientific articles, registered trials, and published patents related to RA treatments was conducted. This review specifically focused on biologic Disease- Modifying Anti-Rheumatic Drugs (biologic DMARDs), small-molecule inhibitors, biomarker- directed personalized medicine, and DDS technologies.

Biologic DMARDs, like Tumor Necrosis Factor (TNF) and interleukin inhibitors, have completely transformed the management of RA by targeting disease mechanisms. Small-molecule inhibitors became available with a similar efficacy to orally bioavailable forms. ADI has improved drug specificity, increased therapeutic efficacy, and decreased systemic toxicity. Biomarker- directed therapy has promise for improving treatment benefit.

Current RA therapies highlight a shift toward biologics, personalized medicine, and advanced drug-delivery systems, enabling targeted action, reduced toxicity, and improved longterm disease management outcomes.

Biologic drugs, small-molecule inhibitors, and DDS technology are revolutionizing treatment for RA. These strategies increase efficacy, decrease side effects, and provide cost-effective, sustained therapy. The intersection of personalized medicine and advanced drug delivery is a future solution for enhancing patient outcomes and quality of life.